French Beverage Stock News

Lagardere (ENXTPA:MMB) is back in focus after reporting first quarter 2026 consolidated revenue of €2,037 million, compared with €1,978 million a year earlier. This provides a fresh data point for investors assessing current performance. See our latest analysis for Lagardere. The quarterly revenue update arrived as Lagardere’s share price sits at €18.6, with a 4.14% 1 month share price return contrasting with a 0.79% 1 year total shareholder return decline, hinting at recent momentum after...

Q1 2026 revenue update and why it matters for Bureau Veritas (ENXTPA:BVI) shareholders Bureau Veritas (ENXTPA:BVI) has just reported first quarter 2026 group revenue of €1,547.0 million, compared with €1,558.7 million a year earlier. This gives investors fresh information on how the testing, inspection and certification group is starting the year. See our latest analysis for Bureau Veritas. The Q1 revenue update arrives after a weak run in the share price, with a 7 day share price return of a...

If you are wondering whether SPIE shares offer fair value at around €48.66, the key is understanding how the current price lines up with different valuation checks. The stock has returned 3.4% over the last week and 14.3% over the last month, while the 1-year return is 20.6% and the 3-year and 5-year returns are 85.3% and 161.1% respectively, with year-to-date performance at a 1.1% decline. Recent coverage has focused on SPIE's role in commercial services and how market expectations are...

Investors in Dassault Systèmes SE ( EPA:DSY ) had a good week, as its shares rose 3.5% to close at €19.60 following the...

Eurofins Scientific (ENXTPA:ERF) has drawn investor attention after a recent pullback, with the share price showing an 11.1% decline over the past week and a 13.3% decline over the past 3 months. See our latest analysis for Eurofins Scientific. The recent pullback comes after a stronger period, with Eurofins Scientific showing a 15.3% 1 year total shareholder return, even as shorter term share price momentum has cooled and recent moves suggest fading near term enthusiasm. If this shift in...

As European markets navigate a landscape marked by geopolitical tensions and economic uncertainties, the pan-European STOXX Europe 600 Index recently experienced a decline, reflecting broader market sentiment. In such an environment, identifying promising small-cap stocks requires careful consideration of factors like resilience to market volatility and potential for growth in traditionally defensive sectors.

Why Clariane’s latest trading update matters for shareholders Clariane (ENXTPA:CLARI) just released its Q1 2026 trading update, reporting revenue of €1,336 million versus €1,317 million a year earlier, alongside a largely oversubscribed €500 million high-yield bond maturing in 2031. See our latest analysis for Clariane. The Q1 2026 update lands after a strong run in recent weeks, with an 18.32% 1 month share price return and a 7.18% 7 day gain. However, the 5 year total shareholder return of...

Rexel stock in focus Rexel (ENXTPA:RXL) is back on investor radars after a recent move in its share price, with the stock last closing at €35.30. This has prompted a closer look at its fundamentals. See our latest analysis for Rexel. Recent trading has been choppy, with a 7.79% 1 month share price return but a 5.51% 7 day share price decline. However, the 1 year total shareholder return of 56.61% points to momentum that still leans positive overall. If Rexel’s move has you watching...

Shareholders appeared unconcerned with ADLPartner SA's ( EPA:DKUPL ) lackluster earnings report last week. We did some...

Kalray earnings: narrowing loss alongside lower revenue Kalray (ENXTPA:ALKAL) has drawn fresh attention after reporting full year 2025 results, with revenue and sales below the prior year, while the net loss narrowed compared with 2024. See our latest analysis for Kalray. The earnings release comes after a sharp shift in market sentiment, with the share price at €8.35 and a 30 day share price return of 146.68%, alongside a very large 1 year total shareholder return and weak 3 year and 5 year...

Bureau Veritas SA recently reported past first-quarter 2026 group revenue of €1,547.0 million, slightly below the €1,558.7 million recorded a year earlier. This small year-on-year revenue decrease offers fresh insight into how the company’s broad testing, inspection, and certification portfolio is performing across its key end-markets. We’ll now examine how this slight year-on-year revenue decline shapes Bureau Veritas’s existing investment narrative and expectations for future...

What stands out in Arkema’s recent performance Arkema (ENXTPA:AKE) has attracted attention after recent trading data showed a 0.0% move over the past day, with a month return of 6.0% and a past 3 months return of 18.9%. See our latest analysis for Arkema. With the share price at €61.7, Arkema’s recent 30 day share price return of 6.0% and 90 day share price return of 18.9% contrast with a 1 year total shareholder return decline of 1.1%, indicating stronger recent momentum than longer term...

Wondering whether Valeo's current share price lines up with its underlying value, especially after a mixed few years for the stock. Recently, the share price has moved around, with a 7 day return of 7.8% decline, a 30 day return of 4.7%, a year to date return of 12.1% decline, and a 1 year return of 26.4%. These swings come alongside ongoing coverage of Valeo's position in the auto components sector and how markets are weighing its prospects against peers. Recent commentary has focused on...

Recent share performance and business scale Without a single clear news event driving SPIE (ENXTPA:SPIE), the recent share performance and business mix provide the main clues for assessing what the current €48.66 price might reflect. The stock shows a 0.1% move over the past week, 14.3% over the past month, and 5.9% over the past 3 months, with a 1 day return of 6.4% and a 1 year total return of 22.5%. SPIE reports revenue of €10.492b and net income of €176.4m, with annual revenue growth of...

Ubisoft Entertainment (ENXTPA:UBI) is in focus after announcing Assassin’s Creed Black Flag Resynced, a rebuilt version of its 2013 title, slated for worldwide multi platform release on 9 July 2026. See our latest analysis for Ubisoft Entertainment. The latest Assassin’s Creed announcement arrives after a 24.8% 1 month share price return, but this sits against a year to date share price decline of 25.4% and a 1 year total shareholder return loss of 54.0%. This suggests sentiment remains...

STMicroelectronics (ENXTPA:STMPA) is back in focus after Q1 2026 revenues came in ahead of expectations, Q2 guidance pointed to further growth, and management underscored AI and data center opportunities. See our latest analysis for STMicroelectronics. The recent Q1 earnings beat, upbeat Q2 revenue guidance and focus on AI and data centers have been met with strong buying interest, with the share price up 80.71% over 3 months and a 1 year total shareholder return of 115.16%, suggesting...

Dassault Systèmes (ENXTPA:DSY) has just reported first quarter 2026 results, with revenue of €1,509.2 million and net income of €292.5 million, alongside confirmed full year guidance and solid cloud and 3DEXPERIENCE traction. See our latest analysis for Dassault Systèmes. The latest earnings and new partnerships around virtual twins, AI and industrial automation have come alongside a 30 day share price return of 18.01%, although the 1 year total shareholder return of a 39.33% decline points...

It's been a sad week for Sartorius Stedim Biotech S.A. ( EPA:DIM ), who've watched their investment drop 14% to €162 in...

Sanofi received FDA approval for Tzield to delay type 1 diabetes in children as young as one year old. The EMA’s CHMP issued a positive opinion for Cenrifki for secondary progressive multiple sclerosis without relapses. The company reported strong Q1 2026 operational performance, supported by recent pharmaceutical launches and broader business momentum. These regulatory wins arrive while ENXTPA:SAN trades around €80.08 and has faced a 9.5% decline over the past year, with returns also...

Wondering if Carrefour at €16.57 is still priced for opportunity or if most of the value story is already reflected in the share price? This article walks you through the key signals to help you frame that question. Over the past year, the stock has returned 31.1%, with a 15.0% year to date move and an 8.0% return over the last 30 days, which puts recent price action firmly on investors' radar. Recent coverage has focused on Carrefour's position in consumer retailing, store network and...

VINCI Energies, part of ENXTPA:DG, has signed a €192 million contract with Guinea's Ministry of Energy. The project includes a 50 MWp solar farm, 350 km of overhead transmission lines and two transformer stations. This renewable energy infrastructure project is located in Guinea and focuses on supporting the country's energy sovereignty. For ENXTPA:DG, this contract highlights VINCI Energies' role in large scale power infrastructure, extending beyond its established European base. The deal...

Investors may be wondering if Exail Technologies at €119.50 is still reasonably priced after such a strong run, or if most of the value is already reflected in the share price. The stock has posted a 0.9% decline over the last 7 days, a 5.2% gain over 30 days, 40.4% year to date, 158.7% over 1 year, and a very large gain over 5 years, which naturally raises questions about what is now priced in. Recent coverage has focused on Exail Technologies as part of ongoing analysis of the stock,...

Guidance confirmation and recent share performance Planisware SAS (ENXTPA:PLNW) confirmed its 2026 earnings guidance, reiterating objectives for low double-digit revenue growth in constant currencies, a data point that can shape how investors think about the stock’s medium term prospects. This guidance update arrives with the shares at €18.42, after a month return of about 32% and a past 3 months return of about 15% decline, while the 1 year total return stands near 16% decline. See our...

If you are wondering whether ABIVAX Société Anonyme at €96.00 is priced attractively or already reflects high expectations, you are in the right place for a closer look at value. The stock has seen mixed recent returns, with around an 8.3% decline over 7 days, a 7.6% gain over 30 days, a 16.5% decline year to date, and a very large gain over the past year that is roughly 15x. Recent attention on ABIVAX Société Anonyme has focused on its role within the broader pharmaceuticals and biotech...